These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26747390)

  • 41. [Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg].
    González-Juanatey JR; Cordero A; Masana L; Dalmau R
    Arch Cardiol Mex; 2024 Jun; ():. PubMed ID: 38843861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
    Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
    Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The polypill: a potential global solution to cardiovascular disease.
    Nguyen C; Cheng-Lai A
    Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Polypill treatments for cardiovascular diseases.
    Webster R; Rodgers A
    Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
    Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP
    Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Could the polypill improve adherence? The patient perspective.
    Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M
    J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Uses of polypills for cardiovascular disease and evidence to date.
    Huffman MD; Xavier D; Perel P
    Lancet; 2017 Mar; 389(10073):1055-1065. PubMed ID: 28290995
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polypills: essential medicines for cardiovascular disease secondary prevention?
    Huffman MD; Yusuf S
    J Am Coll Cardiol; 2014 Apr; 63(14):1368-70. PubMed ID: 24561141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.
    González-Juanatey JR
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):595-596. PubMed ID: 29752030
    [No Abstract]   [Full Text] [Related]  

  • 52. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic Burden Associated with the Treatment with a Cardiovascular Polypill in Secondary Prevention in Spain: Cost-Effectiveness Results of the NEPTUNO Study.
    Cordero A; Dalmau González-Gallarza R; Masana L; Fuster V; Castellano JM; Ruiz Olivar JE; Zsolt I; Sicras-Mainar A; González Juanatey JR
    Clinicoecon Outcomes Res; 2023; 15():559-571. PubMed ID: 37489131
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polypill: the evidence and the promise.
    Lonn E; Yusuf S
    Curr Opin Lipidol; 2009 Dec; 20(6):453-9. PubMed ID: 19884824
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
    Malekzadeh F; Gandomkar A; Malekzadeh Z; Poustchi H; Moghadami M; Fattahi MR; Moini M; Anushiravani A; Mortazavi R; Sadeghi Boogar S; Mohammadkarimi V; Abtahi F; Merat S; Sepanlou SG; Malekzadeh R
    Arch Iran Med; 2020 Aug; 23(8):548-556. PubMed ID: 32894967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polypill: Progress and Challenges to Global Use--Update on the Trials and Policy Implementation.
    Webster R; Rodgers A
    Curr Cardiol Rep; 2015 Dec; 17(12):121. PubMed ID: 26497041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
    Godley RW; Hernandez-Vila E
    Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141
    [No Abstract]   [Full Text] [Related]  

  • 60. The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
    Grigorian-Shamagian L; Coca A; Morais J; Perez-Martinez P;
    BMC Proc; 2023 Aug; 17(Suppl 8):20. PubMed ID: 37587509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.